Greenwich LifeSciences, Inc. Logo

Greenwich LifeSciences, Inc.

Developing an immunotherapy vaccine to prevent recurrence in HER2-positive breast cancer patients.

GLSI | NDAQ

Overview

Corporate Details

ISIN(s):
US3968791083
LEI:
Country:
United States of America
Address:
3992 BLUEBONNET DR, BUILDING 14, 77477 STAFFORD
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company pioneering the development of GLSI-100 (also known as GP2), an immunotherapy to prevent the recurrence of breast cancer. The company's lead candidate is a peptide-based vaccine designed to activate the immune system to target HER2-positive cancer cells. GLSI-100 is aimed at patients who have undergone surgery and completed standard-of-care treatments. Following a successful Phase IIb trial that showed a significant reduction in recurrence rates and a well-tolerated safety profile, the therapy is now advancing through a global Phase III clinical trial, Flamingo-01. The treatment has been granted Fast Track Designation by the U.S. FDA, highlighting its potential to address a critical unmet need in oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Greenwich LifeSciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Greenwich LifeSciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Greenwich LifeSciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Crossject Logo
Develops needle-free auto-injectors for rapid drug delivery in medical emergencies.
France ALCJ
CTC BIO, INC. Logo
Develops pharmaceuticals and feed additives for human and animal health using fermentation tech.
South Korea 060590
Cue Biopharma, Inc. Logo
Develops injectable biologics to selectively activate T cells for oncology & autoimmune disease.
United States of America CUE
Cullinan Therapeutics, Inc. Logo
Developing differentiated immune-modulating therapies for cancer and autoimmune diseases.
United States of America CGEM
CUMBERLAND PHARMACEUTICALS INC Logo
Acquires and commercializes branded medicines for acute care, gastroenterology, and oncology.
United States of America CPIX
Cuorips Inc. Logo
Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.
Japan 4894
Cuprina Holdings (Cayman) LTD Logo
Biomedical firm specializing in Maggot Debridement Therapy for wound care in Singapore & Hong Kong.
United States of America CUPR
curacle co., ltd. Logo
Developing drugs for intractable diseases like diabetes caused by vascular damage and aging.
South Korea 365270
Curanex Pharmaceuticals Inc Logo
Developing botanical drugs for inflammatory diseases, diabetes, and COVID-19.
United States of America CURX
Curevac Logo
Pioneering mRNA technology to create vaccines and therapies for infectious diseases, cancer, and more.
Germany CVAC

Talk to a Data Expert

Have a question? We'll get back to you promptly.